Prices, costs, and affordability of new medicines for Hepatitis C in 30 countries: An economic analysis

New hepatitis C virus (HCV) medicines have markedly improved treatment efficacy and regimen tolerability. However, their high prices have limited access, prompting wide debate about fair and affordable prices. This study systematically compared the price and affordability of sofosbuvir and ledipasvir/sofosbuvir across 30 countries to assess affordability to health systems and patients.

Original Source

Related Content

blog comments powered by Disqus